ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

tirabrutinib

Also written as “Tirabrutinib” and “ONO-4059”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Pemphigus · Chronic Urticaria · Lymphoma, Non-Hodgkin · Sjogren's Syndrome, led by 2 companies.

Drug pageTirabrutinib: every studyAll 14 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 16, 201613 company-led studies, 4 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only80 open or runningphase 2since Nov 16, 2016Jul 6, 2012none ahead
Ono Pharmaceutical54 open or runningphase 3since Nov 7, 2024Jun 16, 2021Sep 30, 2027phase 3 · NCT06696716

Also a collaborator on its studies: Lakefront Biotherapeutics NV.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ono Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2016Named tirabrutinibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, ONO-4059
  2. Jun 16, 2021First study: phase 2 study in Refractory Primary Central Nervous System LymphomaFirst studyNCT04947319 · 119 enrolled · United States
  3. Aug 2, 2024Phase 1 study in Primary Central Nervous System LymphomaNCT06541665 · 20 enrolled · Japan
  4. Nov 7, 2024Phase 3 study in PemphigusNCT06696716 · 34 enrolled · Japan
  5. Jul 29, 2025Phase 3 study in RecurrenceNCT07104032 · 132 planned · United States, Australia, Brazil and more
  6. Aug 31, 2025Phase 1 study in Primary Central Nervous System Lymphoma (PCNSL)NCT07198087 · 40 enrolled · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in PemphigusNCT06696716
  2. Dec 2027Primary completion: phase 3 study in RecurrenceNCT07104032
  3. Apr 28, 2028Primary completion: phase 1 study in Primary Central Nervous System LymphomaNCT06541665

TargetBeta

BTK →read by rule
“An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 5 Ono Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07198087Primary Central Nervous System Lymphoma (PCNSL) · United States1CompletedApr 9, 202640
NCT07104032Recurrence · United States, Australia, Brazil and more3RecruitingDec 2027132
NCT06696716Pemphigus · Japan3Active, not recruitingSep 30, 202734
NCT06541665Primary Central Nervous System Lymphoma · Japan1Active, not recruitingApr 28, 202820
NCT04947319Refractory Primary Central Nervous System Lymphoma · United States2Active, not recruitingJan 27, 2026119

How it is read

Names in the registry

  • “Tirabrutinib”, 13 entries
  • “ONO-4059”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.